Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    EbolaEBOVand MarburgMARVviruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period ofdaysDue to safety concernsthese viruses are designated as biosafety levelagentsCurrentlythere is no effective vaccine or therapeutic treatment for filoviral infections in humansAfrica has recentlysuffered a lethal EBOV e ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary Abstract Kidney stonesKSare highly prevalentexcruciatingand associated with long term complications of chronic kidney diseaseCKDand end stage renal diseaseESRDThey account forM ER visits and andgt $B of medical costs annually and have a striking recurrence rate ofinyears and up toinyearsreflecting the inadequacies of current interventionsof KS are composed of calcium oxalate and sm ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics

    SBC: Neurolux, Inc.            Topic: 101

    Project Summary Abstract Neuroscience research over the last decade has been revolutionized by many technological advancementsPharmacology and optogenetics represent two distinctand sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiativeAdvanced interrogations of underlying neural circuits and biology ar ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission

    SBC: EDEN PARK ILLUMINATION, INC.            Topic: NIAID

    Drug resistant bacteria such as MRSAand airborne transmitted microbes such as influenza and TBpresent significant health issueswith major healthcare and economic consequencesUV light is a well established highly efficient anti microbial modalityeffective both against both bacteria and virusesHowever it is not possible to use UV sterilization in scenarios where people are present because it is both ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy

    SBC: Nano Biotherapeutics, Inc.            Topic: NHLBI

    Sepsis induced ALI ARDS is a devastating syndrome of acute respiratory failure in critically ill patients that accounts for among the highest admission rates in ICU and mortalityDuring STTR Phasewe at Cell Biologics Incdemonstrated that piceatannola naturally occurring anti inflammatory that selectively inhibits Syk tyrosine kinasewhen entrapped in innm albumin nanoparticlesPANPswas therapeuticall ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: Microelectronics Research Development Corporation            Topic: DTRA16A003

    Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
US Flag An Official Website of the United States Government